Company Description
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus.
The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names.
It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).
In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand.
It serves wholesalers and retail healthcare providers. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2009 |
| IPO Date | Dec 13, 2013 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 149 |
| CEO | Grigorios Siokas |
Contact Details
Address: 141 West Jackson Boulevard, Suite 4236 Chicago, Illinois 60604 United States | |
| Phone | 312 536 3102 |
| Website | cosmosholdingsinc.com |
Stock Details
| Ticker Symbol | COSM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001474167 |
| CUSIP Number | 221413206 |
| ISIN Number | US2214133058 |
| Employer ID | 27-0611758 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Grigorios Siokas | Chairman and Chief Executive Officer |
| Georgios Terzis | Chief Financial Officer |
| Nikolaos Bardakis | Chief Operating Officer |
| Demetrios G. Demetriades | Secretary and Independent Director |
| Prof. Dimitrios Trafalis | Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 22, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 19, 2025 | SCHEDULE 13G/A | Filing |
| Aug 18, 2025 | 10-Q | Quarterly Report |
| Aug 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | PRE 14A | Other preliminary proxy statements |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jun 3, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 27, 2025 | SCHEDULE 13D/A | Filing |